Carlos Zamora Atenza

6PUBLICATIONS
23CO-AUTHORS
Predictive and prognostic markersAutoimmunityCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 01, 2026
Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial).

Aida Piedra, Albert Guinart-Cuadra, Sergio Martínez-Recio

|Oct 27, 2022
Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.

Leticia Alserawan, Geòrgia Anguera, Carlos Zamora Atenza

|Dec 24, 2021
Effector Mechanisms of CD8+ HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy.

Rubén Osuna-Gómez, Cristina Arqueros, Carla Galano

|Sep 28, 2021
Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy.

Elisabet Cantó, Óscar Rodríguez Faba, Carlos Zamora

|May 05, 2021
Phenotypic and Functional Consequences of PLT Binding to Monocytes and Its Association with Clinical Features in SLE.

Anaís Mariscal, Carlos Zamora, Berta Magallares

|Apr 05, 2019
Association of Platelet Binding to Lymphocytes with B Cell Abnormalities and Clinical Manifestations in Systemic Lupus Erythematosus.

Carlos Zamora, Elide Toniolo, Cesar Diaz-Torné

Pageof 1

Frequent Collaborators

2 joint publications

Silvia Vidal

2 joint publications

Maria Angels Ortiz

2 joint publications

Margarita Majem Tarruella

2 joint publications

Jorgina Serra-López